Global Tumor Necrosis Factor Inhibitor Drugs Market Set For Moderate Growth, To Reach Value around USD 42.08 Billion by 2025

18-Feb-2020 | Zion Market Research

Zion Market Research has published a new report titled “Tumor Necrosis Factor Inhibitor Drugs Market by Product (Biosimilars, Cimzia, Simponi/Simponi Aria, Remicade, Enbrel and Humira); by Application (Psoriasis, Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn’s Disease, Hidradenitis Suppurativa, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis and Other Applications); By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 – 2025”. According to the report, global demand for tumor necrosis factor inhibitor drugs market was valued at approximately USD 40.23 billion in 2018, and is expected to generate revenue of around USD 42.08 billion by end of 2025, growing at a CAGR of around 0.7% between 2019 and 2025.

Browse the full “Tumor Necrosis Factor Inhibitor Drugs Market by Product (Biosimilars, Cimzia, Simponi/Simponi Aria, Remicade, Enbrel and Humira); by Application (Psoriasis, Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn’s Disease, Hidradenitis Suppurativa, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis and Other Applications); By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 – 2025.” Report at https://www.zionmarketresearch.com/report/tumor-necrosis-factor-inhibitor-drugs-market

Request Sample Request Customization Buy Now

Tumor necrosis factor (TNF) is secreted by immune cells that cause inflammation in the body and is a multifunctional protein cytokine that plays vital role in a large number of cellular functions including cell proliferation, survival, differentiation, and death. Body’s innate response to tumor necrosis factor (TNF) is suppressed by tumor necrosis factor inhibitors. Inflammatory conditions such as psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, psoriasis, etc. are treated with are TNF inhibitor drugs. Also, autoimmune disorders are treated with TNF inhibitor drugs and are used to avoid immune system attacking from healthy body cells.

The tumor necrosis factor inhibitor drugs market growth is fueled by various factors such as growing prevalence of autoimmune disorders across the globe, promising drug pipelines, growing elderly population base, new product launches, increasing disposable income, increasing healthcare expenditure, and increasing health awareness. However, intense competition from interleukin inhibitors, emergence of new biosimilars due to loss of patent exclusivity, and internal threat from biosimilars are factors that may impede the market growth in the coming years. Increasing preference for cost effective therapies with better safety and efficacy are projected to open new growth avenues for market players during the forecast period.

Tumor necrosis factor inhibitor drugs market is segmented based on product, application, distribution channel and region. Based on product, market is bifurcated into Cimzia, Biosimilars, Simponi/Simponi Aria, Remicade, Humira and Enbrel. Humira was the leading product segment 2018 and is projected to retain its dominance in the coming years. This is due to patent exclusivity of Humira in U.S. which is expiring in 2023. Rapid growth is projected for biosimilars product segment as a result of new product launches, promising drug pipeline and patent expiry of major brands.

Based on applications, tumor necrosis factor inhibitor drugs market is segmented into psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, psoriasis, hidradenitis suppurativa, Crohn’s disease, ankylosing spondylitis, juvenile idiopathic arthritis, and other applications. Market was dominated by rheumatoid arthritis application segment in 2018. Growth of rheumatoid arthritis application segment is driven by increasing health awareness, growing prevalence of rheumatoid arthritis, and high treatment rate. Fastest growth is projected for psoriasis and psoriatic arthritis application segments over the forecast period.

Based on distribution channel market for TNF inhibitor drugs is segmented into online pharmacies hospital pharmacies, and specialty pharmacies. Hospital pharmacies held leading market share in 2018. Rapid growth is projected for online pharmacies distribution channel segment in the coming years.

At regional level, North America held largest market share for the global tumor necrosis factor inhibitor drugs in 2018. This large share is attributed to strong commercial sales, presence of key players, favorable reimbursement policies, growing health awareness and increasing patient pool in this region. Europe was second leading regional market in terms of market share. Growing numbers of autoimmune disorder cases, availability of developed infrastructure, and growing health awareness are major factors that propel market growth in this region. Asia Pacific region is estimated to be rapidly growing tumor necrosis factor inhibitor drugs market. Rapid growth in this region is attributed to economic development, investments on healthcare infrastructure improvement, growing elderly population base, increasing disposable income and healthcare spending, and increasing health awareness. Middle East and Africa and Latin America are projected to witness moderate growth over the forecast period.

Major players in tumor necrosis factor inhibitor drugs market are Merck & co., Inc., Pfizer, Inc., Novartis International AG, UCB S.A., Johnson & Johnson Services, Inc., Amgen Inc., and AbbVie Inc. among others.

The report segment of global tumor necrosis factor inhibitor drugs market as follows:

Global Tumor Necrosis Factor Inhibitor Drugs Market: Product

  • Humira
  • Enbrel
  • Remicade
  • Simponi/Simponi Aria
  • Cimzia
  • Biosimilars

Global Tumor Necrosis Factor Inhibitor Drugs Market: By Application

  • Rheumatoid Arthritis
  • Psoriasis
  • Psoriatic Arthritis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis
  • Hidradenitis Suppurativa
  • Others

Global Tumor Necrosis Factor Inhibitor Drugs Market: By Distribution Channel

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies

Global Tumor Necrosis Factor Inhibitor Drugs Market: By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com

Request Brochure
Latest Published Reports

View All Published Reports